{"id":9165,"date":"2017-10-05T07:45:00","date_gmt":"2017-10-05T05:45:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/"},"modified":"2017-10-05T07:45:00","modified_gmt":"2017-10-05T05:45:00","slug":"irlab-erhaller-tillstand-fran-finska-lakemedelsverket","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/","title":{"rendered":"IRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

IRLAB Therapeutics AB har nu \u00e4ven erh\u00e5llit finska l\u00e4kemedelsverkets (FIMEA) och etiska kommitt\u00e9ns vid Universitetssjukhuset i Turkku tillst\u00e5nd att genomf\u00f6ra Fas II-studien med l\u00e4kemedelskandidaten IRL752 i Finland. Den 25 augusti 2017 meddelade IRLAB att bolaget f\u00e5tt tillst\u00e5nd fr\u00e5n svenska L\u00e4kemedelsverket att starta studien i Sverige.<\/strong><\/div>\n

\u201dDet \u00e4r mycket tillfredst\u00e4llande att \u00e4nnu en l\u00e4kemedelsmyndighet har granskat v\u00e5r l\u00e4kemedelskandidat IRL752, och givit sitt tillst\u00e5nd till klinisk pr\u00f6vning. Att vi nu kan rekrytera patienter \u00e4ven i Finland inneb\u00e4r att studien f\u00f6rst\u00e4rks med erfarna finska experter med l\u00e5ng erfarenhet fr\u00e5n behandling av Parkinsons sjukdom\u201d, s\u00e4ger Joakim Tedroff, IRLAB:s medicinska chef, CMO.<\/p>\n

Fas II-studien, som \u00e4r randomiserad, dubbelblind och placebokontrollerad, kommer att studera hur kognitiva och motoriska funktioner p\u00e5verkas av behandling med IRL752 hos patienter med Parkinsons sjukdom och demens. Studiens prim\u00e4ra syfte \u00e4r att unders\u00f6ka s\u00e4kerhet och tolererbarhet av IRL752.<\/p>\n

\n

F\u00f6r vidare information<\/strong><\/p>\n

Nicholas Waters, VD\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Tel: +46 730 75 77 01\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0\u00a0
E-post: nicholas.waters@irlab.se<\/a><\/p>\n

Joakim Tedroff, CMO\u00a0
Tel: +46 70\u00a0760 16 91
E-post: joakim.tedroff@irlab.se<\/a><\/p>\n

Denna information \u00e4r s\u00e5dan information som IRLAB Therapeutics AB (publ) \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersoners f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 5 oktober 2017 kl. 07.45 CET.<\/p>\n

FNCA Sweden AB \u00e4r Bolagets Certified Adviser p\u00e5 Nasdaq First North Premier.<\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

IRLAB \u00e4r ett forsknings- och utvecklingsbolag, listat p\u00e5 Nasdaq First North Premier som fokuserar p\u00e5 utveckling av nya l\u00e4kemedel f\u00f6r behandling av neurodegenerativa sjukdomar, i synnerhet Parkinsons sjukdom och demens.<\/p>\n

IRLAB har tv\u00e5 kliniska l\u00e4kemedelskandidater, IRL752 och IRL790, inriktade mot medicinska behov vid Parkinsons sjukdom, samt ytterligare projekt i preklinisk fas.<\/p>\n

IRLAB:s forskning syftar till att uppt\u00e4cka och utveckla nya l\u00e4kemedelskandidater f\u00f6r behandling av hj\u00e4rnans sjukdomar, d\u00e4r stora medicinska behov idag f\u00f6religger. Med hj\u00e4lp av den unika systembiologiska forskningsplattformen, ISP, uppt\u00e4cks dess nya behandlingsprinciper.<\/p>\n

IRLAB \u00e4r baserat i G\u00f6teborg. IRLAB:s verksamhet bedrivs huvudsakligen genom dotterbolaget Integrative Research Laboratories Sweden AB.<\/p>\n

F\u00f6r mer information, v\u00e4nligen bes\u00f6k\u00a0www.irlab.se<\/a>.<\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

IRLAB Therapeutics AB har nu \u00e4ven erh\u00e5llit finska l\u00e4kemedelsverkets (FIMEA) och etiska kommitt\u00e9ns vid Universitetssjukhuset i Turkku tillst\u00e5nd att genomf\u00f6ra Fas II-studien med l\u00e4kemedelskandidaten IRL752 i Finland. Den 25 augusti 2017 meddelade IRLAB att bolaget f\u00e5tt tillst\u00e5nd fr\u00e5n svenska L\u00e4kemedelsverket att starta studien i Sverige.<\/p>\n","protected":false},"template":"","class_list":["post-9165","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket - IRLAB\" \/>\n<meta property=\"og:description\" content=\"IRLAB Therapeutics AB har nu \u00e4ven erh\u00e5llit finska l\u00e4kemedelsverkets (FIMEA) och etiska kommitt\u00e9ns vid Universitetssjukhuset i Turkku tillst\u00e5nd att genomf\u00f6ra Fas II-studien med l\u00e4kemedelskandidaten IRL752 i Finland. Den 25 augusti 2017 meddelade IRLAB att bolaget f\u00e5tt tillst\u00e5nd fr\u00e5n svenska L\u00e4kemedelsverket att starta studien i Sverige.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/\",\"name\":\"IRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2017-10-05T05:45:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket - IRLAB","og_description":"IRLAB Therapeutics AB har nu \u00e4ven erh\u00e5llit finska l\u00e4kemedelsverkets (FIMEA) och etiska kommitt\u00e9ns vid Universitetssjukhuset i Turkku tillst\u00e5nd att genomf\u00f6ra Fas II-studien med l\u00e4kemedelskandidaten IRL752 i Finland. Den 25 augusti 2017 meddelade IRLAB att bolaget f\u00e5tt tillst\u00e5nd fr\u00e5n svenska L\u00e4kemedelsverket att starta studien i Sverige.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/","name":"IRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2017-10-05T05:45:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-erhaller-tillstand-fran-finska-lakemedelsverket\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB erh\u00e5ller tillst\u00e5nd fr\u00e5n finska l\u00e4kemedelsverket"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/9165","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=9165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}